As Anthropic pushes deeper into life sciences, the FDA is sharpening rules around AI‑enabled research and the use of computational predictions in regulated development pipelines.
Life Sciences
The EU has tasked EQT to head the new €5 billion ($5.8 billion) fund aimed at keeping Europe’s most promising tech companies from scaling abroad.
GRIP will partner with Informa Connect’s Pharmaceutical Compliance Congress: Canada to capture how compliance leaders are helping the industry innovate responsibly amid regulatory complexity.
The partnership will introduce Anthropic’s Claude’s agentic AI capabilities into research, clinical development, manufacturing, commercial operations, and corporate functions.
Announcement comes as global pharmaceutical markets shift, with Canada facing pressure to secure investments and ensure timely access to new therapies.
At PCC 2026, pharma attendees heard that companies need to balance automation with human oversight while navigating evolving expectations around transparency, risk, and ethical implementation.
What the ECJ's landmark ruling on defective products liability means for life sciences manufacturers
This article covers the expanded litigation risk, the steps life science companies should take to reinforce their product safety, and risk‑management governance.
Proactive steps companies in the healthcare sector (or those that insure or invest in those businesses) should take now.